UConn's Justin Radolf on Immune Suppression by Pam3Cys (OspA)

[Mort Zuckerman]

To: emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, the-...@nytimes.com, biz...@nytimes.com,
for...@nytimes.com, nati...@nytimes.com, dv...@cdc.gov,
brigidc...@optonline.net, tr...@hotmail.com, illino...@aol.com,
jle...@courant.com, tinaj...@yahoo.com, jhorn...@fff.org,
thomas...@usdoj.gov, thoma...@po.state.ct.us,
kur...@washpost.com, georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, sidney_b...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org

Subject: UConn's Justin Radolf on Immune Suppression by Pam3Cys (OspA)

Date: Mar 15, 2009 7:36 AM

'Never says a word about this while
LYMErix (Pam3Cys) was still on the market.
'Never says a word about LYMErix causing
immune suppression.
'Same with Gary Wormser:
http://www.ncbi.nlm.nih.gov/pubmed/10865170?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

While LYMErix was still on the market, neither
of them said there is a problem with OspA vaccination.

In fact, Wormser is promoting another OspA vaccine
in order to lie about the outcomes of the first
one. Meanwhile the entire, global medical world
is in shock about HIV-LYMErix:
http://www.actionlyme.org/PAM3CYS_LYME_HIV.htm
http://www.actionlyme.org/080924.htm

The New York Times and JAMA are unable to run
a story about it either?

Fauci interviewed by NEJM:
http://content.nejm.org/cgi/content/extract/359/9/888
"The initial empirical approach of immunizing with VaxGen's AIDSVax, a
recombinant form of the outer glycoprotein-120 (gp120) portion of the
HIV envelope, which was based on a strategy that was successful with
hepatitis B, failed to protect volunteers from infection, apparently
because the vaccine did not induce broadly neutralizing antibodies.3

Here's why:
http://www.actionlyme.org/PAM3CYS_IMMUNE_SUPPRESSION.htm

C R I M E



http://www.ncbi.nlm.nih.gov/pubmed/11441098?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum


J Immunol. 2001 Jul 15;167(2):910-8.Click here to read Links
Toll-like receptor 2-dependent inhibition of macrophage class II MHC
expression and antigen processing by 19-kDa lipoprotein of
Mycobacterium tuberculosis.
Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT,
Boom WH, Harding CV.

Department of Pathology, Case Western Reserve University and
University Hospitals of Cleveland, Cleveland, OH 44106, USA.

Mycobacterium tuberculosis (MTB) induces vigorous immune
responses, yet persists inside macrophages, evading host immunity. MTB
bacilli or lysate was found to inhibit macrophage expression of class
II MHC (MHC-II) molecules and MHC-II Ag processing. This report
characterizes and identifies a specific component of MTB that mediates
these inhibitory effects. The inhibitor was extracted from MTB lysate
with Triton X-114, isolated by gel electroelution, and identified with
Abs to be MTB 19-kDa lipoprotein. Electroelution- or immunoaffinity-
purified MTB 19-kDa lipoprotein inhibited MHC-II expression and
processing of both soluble Ags and Ag 85B from intact MTB bacilli.
Inhibition of MHC-II Ag processing by either MTB bacilli or purified
MTB 19-kDa lipoprotein was dependent on Toll-like receptor (TLR) 2 and
independent of TLR 4. Synthetic analogs of lipopeptides from Treponema
pallidum also inhibited Ag processing. Despite the ability of MTB 19-
kDa lipoprotein to activate microbicidal and innate immune functions
early in infection, TLR 2-dependent inhibition of MHC-II expression
and Ag processing by MTB 19-kDa lipoprotein during later phases of
macrophage infection may prevent presentation of MTB Ags and decrease
recognition by T cells. This mechanism may allow intracellular MTB to
evade immune surveillance and maintain chronic infection.

"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci